QualityStocks would like to highlight Zynex Medical (OTCBB: ZYXI). The company engineers, manufactures, markets and sells its own design of electrotherapy medical devices for electrotherapy, used for pain management and rehabilitation. Zynex, operates under three primary business segments; Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring Solutions. Zynex Medical’s product lines are fully developed, FDA-cleared and commercially sold world-wide. Zynex NeuroDiagnostics, sells the company's proprietary NeuroMove device designed to help stroke and spinal cord injury patients and is currently expanding into markets for EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development and acquisitions. Zynex Monitoring Solutions, currently in the development stage, has been established to develop and market medical devices for non-invasive cardiac monitoring.
In the company’s news yesterday,
Zynex posted its first quarter 2012 unaudited financial results.
The company’s total first-quarter net revenue increased 35 percent to $8.9 million compared to $6.6 million reported for the first quarter of the year prior. The company attributes the increase in sales to its Zynex Medical subsidiary, in which strong demand continues from its products. A small amount of revenue was derived from its Zynex NeuroDiagnostics subsidiary.
First quarter 2012 net income was $320,000, or $0.01 per share, versus a net loss of $110,000, or less than $(0.01) per share in the first quarter of 2011.
Gross profit for the quarter was $7.1 million, or 80 percent of net revenue, compared to a gross profit of $5.1 million, or 78 percent of net revenue, for the comparable three months of 2011.
Zynex CEO Thomas Sandgaard said the first few months of the year are typically the slowest for the company as it represents a reset for most patient insurance deductibles, which lowers the amount of expected revenue the company can report. As such, Sandgaard said the increase in first-quarter revenues reflects solid demand.
“Achieving a 35% increase in net revenue is representative of the strong demand for our Zynex Medical electrotherapy products and volume of orders we continue to obtain quarter over quarter,” Sandgaard stated in the press release.
The company also confirmed its initial guidance of anticipated total net revenue of between $38 million and $40 million for 2012 and net income per diluted share of between $0.06 and $0.08 for 2012.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.